Impact of illegal trade on the quality of epoetin alfa in Thailand

Clinical Therapeutics

Volumn 31, Issue 2, 2009, Pages 336-346

  Fotiou, Fotis ^a   Aravind, Suresh ^b   Wang, Ping Ping ^c   Nerapusee, Osot ^d  

^a Johnson and Johnson   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c Pharmaceutical Science   (United States)

^d Janssen Cilag Bangkok   (Thailand)

Author keywords

epoetin alfa; illegal trade; pure red cell aplasia; smuggling; Thailand

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

AIRPORT; ARTICLE; DRUG CONTROL; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG QUALITY; DRUG SAFETY; DRUG SCREENING; DRUG TRAFFIC; GEL ELECTROPHORESIS; HOSPITAL PHARMACY; OUTCOME ASSESSMENT; PROTEIN AGGREGATION; SAMPLING; SYRINGE; THAILAND; WESTERN BLOTTING;

COMMERCE; CRIME; DRUG AND NARCOTIC CONTROL; DRUG CONTAMINATION; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; EPOETIN ALFA; HEMATINICS; HUMANS; PHARMACOPOEIAS AS TOPIC; PHARMACY; QUALITY CONTROL; RED-CELL APLASIA, PURE; SYRINGES; THAILAND;

EID: 62549141493     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.02.014     Document Type: Article

References (16)

1. Percheson P., Aravind A., Vercammen E., et al. Review of PRCA in Thailand (2004-2007): An update on the investigation into the recent anti-EPO antibody-mediated PRCA cases in Thailand (2008), Johnson & Johnson Pharmaceutical Research and Development, Bangkok, Thailand
2. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 1 (2002) 457-462
3. World Health Organization (WHO). Counterfeit medicines. Fact sheet no. 275. Revised 14 November 2006 [WHO Web site]. http://www.who.int/mediacentre/factsheets/fs275/en/print.html Accessed June 25, 2008
4. Jack A. Counterfeit medicines. Bitter pills. BMJ. 335 (2007) 1120-1121
5. Janssen-Cilag Ltd. Electronic Medicines Compendium, Eprex 2000, 4000, 10000 IU/ml pre-filled syringes. 6.4 Special precautions for storage. http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID= 889#SHELF_LIFE Accessed November 10, 2008
6. Erythropoietin concentrated solutions. Pharmeuropa 14.1 (January 2002) 94-99. http://www.edqm.eu/medias/fichiers/Pharmeuropa_Contents_141.pdf Accessed February 2, 2009
7. ®. European Journal of Hospital Pharmacy Practice 5 (2004) 86-91. http://www.eahp.eu/EJHP/EJHP-Practice/Issue-5-2004/Industry-science/Tech nical-investigations-into-the-cause-of-the-increased-incidence-of-antibo dy-mediated-pure-red-cell-aplasia-associated-with-EPREXA-R Accessed February 2, 2009
8. Rosenberg A.S. Effects of protein aggregates: An immunologic perspective. AAPS J. 8 (2006) E501-E507
9. Hochuli E. Interferon immunogenicity: technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res. 17 Suppl 1 (1997) S15-S21
10. Rosendaal F.R., Nieuwenhuis H.K., van den Berg H.M., et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood. 81 (1993) 2180-2186
11. Schellekens H. Biosimilar epoetins: How similar are they?. Euro Hosp Pharm 3 (2004) 243-247. http://www.eahp.eu/EJHP/EJHP-Practice/Issue-3-2004/Scientific-section/Bi osimilar-epoetins-how-similar-are-they Accessed January 20, 2009
12. Schmidt C.A., Ramos A.S., da Silva J., et al. Evaluation of the activity and characterization of recombinant human erythropoietin in pharmaceuticals [in Portuguese]. Arq Bras Endocrinol Metab 47 (2003) 183-189. http://www.scielo.br/pdf/abem/v47n2/a12v47n2.pdf Accessed June 25, 2008
13. Singh A. Gaps in the quality and potential safety of biosimilar epoetins in the developing world: An international survey. Presented at the XLIV ERA-EDTA Congress (June 21-24, 2007) Barcelona, Spain. Abstract SaP350
14. Keithi-Reddy S.R., Kandasamy S., and Singh A.K. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 74 (2008) 1617-1622
15. U.S. Food and Drug Administration (FDA). (FDA) Consumer magazine: Curbing counterfeit drugs [FDA Web site]. September-October 2006. http://www.fda.gov/fdac/features/2006/506_counterfeit.html Accessed June 25, 2008
16. Zumoff R. WHO reports counterfeit drugs are a global calamity. Nephrol News Issues. 21 (2007) 22